(Reuters) - WASHINGTON - U.S. regulators are reviewing the safety of GlaxoSmithKline's Plc's diabetes drug Avandia but have not yet determined the significance of risks reported in a study released on Monday, a U.S. Food and Drug Administration official said.
A study published in the New England Journal of Medicine said Avandia increased the risk of cardiac-related deaths by 64 percent and heart attacks by 43 percent. Dr. Robert Meyer, head of the FDA office that reviews diabetes drugs, said other data contradicted those findings.
Read more at Reuters.com Business News
A study published in the New England Journal of Medicine said Avandia increased the risk of cardiac-related deaths by 64 percent and heart attacks by 43 percent. Dr. Robert Meyer, head of the FDA office that reviews diabetes drugs, said other data contradicted those findings.
Read more at Reuters.com Business News
No comments:
Post a Comment